Strategy
MSTR
MARA Holdings
MARA
NVIDIA
NVDA
Tesla
TSLA
Coinbase
COIN
US Stock MarketDetailed Quotes
APVO Aptevo Therapeutics
- 3.820
- +0.230+6.41%
Close Feb 28 16:00 ET
- 3.500
- -0.320-8.38%
Post 20:01 ET
5.57MMarket Cap-0.04P/E (TTM)
4.000High3.480Low59.61KVolume3.550Open3.590Pre Close222.05KTurnover4.09%Turnover RatioLossP/E (Static)1.46MShares399.60052wk High1.17P/B5.57MFloat Cap3.01052wk Low--Dividend TTM1.46MShs Float144729.200Historical High--Div YieldTTM14.48%Amplitude3.010Historical Low3.725Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Aptevo Therapeutics Stock Forum
Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission Rate - CEO Interview Alert
The clinical data presented by Aptevo Therapeutics demonstrates remarkable efficacy signals that warrant careful attention. In the RAINIER trial, mipletamig's 100% remission rate within 30 days in Cohort 1 is particularly noteworthy, as typical remission rates for standard venetoclax/azacitidine therapy in AML range from 65-70%. The achievement of MRD negativity in one patient is espec...
Groundbreaking AML Trial Results: Aptevo's New Drug Achieves Perfect Remission Score While Solid Tumor Program Shows Promise
typically how it works is they run the commercials and then they'll drop some news within a day or two to try to jump start the stock price
No comment yet